Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Active Pass Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

A biotech start-up seeking to establish itself in the area of Alzheimer's disease (AD) faces the daunting task of competing in an arena already populated by a contingent of large drug companies that are expending considerable resources in the hopes of developing the sort of blockbuster product with which Big Pharma is so obsessed. But Peter Reiner, VMD, PhD, president and CEO of Active Pass Pharmaceuticals Inc., argues that his company can carve a niche for itself with a novel technology for treating AD that may also provide a platform for developing therapeutics in a number of other major disease areas.
Advertisement

Related Content

New Approaches for Neurodegenerative Disorders

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090283

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel